Whippets and Laughing Gas: How Nitrous Oxide Damages Nerves, and Why a Normal B12 Test Can Miss It

Nitrous oxide is the most ordinary-looking drug in America. It arrives in a box printed with cartoon fruit, sold openly as a food-grade product — the same gas that pressurises a whipped-cream dispenser, decanted into balloons at a party. There is no smell, no needle, no come-down worth mentioning, and a standard urine drug screen will not find it.

It is also, in the last decade, a recognisable cause of permanent spinal cord injury in people in their twenties. One 2026 pharmacy review estimates that more than 13 million people in the United States have used nitrous oxide recreationally, that poison centre calls about it rose 1,300% between 2003 and 2024, and that deaths involving it increased six-fold between 2010 and 2023. The people showing up in neurology clinics are not the people most families picture when they worry about drugs.

Here is how it damages nerves — and what a family can still do.

Why It Is Suddenly Everywhere

Nitrous oxide has been used in medicine for over a century — it is a genuine anaesthetic and pain reliever, still used in dentistry and in some hospital settings, and it appears in NIDA's inhalant category alongside butane and solvents.

Recreational use is a different exposure. NIDA describes the retail form plainly: small vials known as whippets or chargers, releasing gas into whipped cream dispensers, bags, or balloons. What changed in the last few years is scale and marketing. The 2026 review in Current Medical Research and Opinion describes a market that now sells large-volume flavoured canisters "with easy and discreet access for children and young adults in formulations that attract them" — sold as cooking aids, delivered to the door, promoted on video platforms. A separate 2025 review in Cureus describes the same pattern as large-volume flavoured canisters exploiting legal loopholes.

Official surveillance barely registers it. National surveys count nitrous oxide inside the broader inhalant category rather than reporting it on its own. In NIDA's summary of that data, fewer than 1% of Americans aged 12 and older reported past-year inhalant use in 2023, but about 4% of eighth graders — children around 14 — had used an inhalant in the past year, and roughly 300,000 people met criteria for inhalant use disorder. Inhalants remain a younger adolescent's drug of first experimentation, and nitrous oxide is the most socially acceptable member of that family.

That combination is what makes it hard for families: the harm is real, the exposure looks harmless, and nothing in the culture — including the law, in most of the country — signals caution.

What the Gas Actually Does to Vitamin B12

The high lasts roughly thirty seconds to a minute. Nitrous oxide is a dissociative anaesthetic: it briefly interrupts normal signalling in the brain, producing euphoria, floating sensations, distorted sound, and sometimes giggles — hence "laughing gas."

The injury has nothing to do with that minute. It comes from what the gas does to vitamin B12, chemically, every time it is inhaled.

Vitamin B12 works because of a cobalt atom at its centre. Nitrous oxide oxidises that cobalt ion, and in doing so irreversibly inactivates the vitamin. The molecule is not destroyed in the sense that a blood test stops finding it; it is disabled. The body has to replace it with fresh B12, and while a person keeps using, it cannot keep up.

Disabled B12 cannot run methionine synthase, an enzyme that recycles homocysteine into methionine. Two things follow, and both are measurable:

• Homocysteine accumulates. In one hospital cohort, the median level in symptomatic users was 50 µmol/L, against a normal range of 5–15.
• Methylmalonic acid (MMA) accumulates. Median 0.68 µmol/L against a normal ceiling of 0.27.

Methionine is also the raw material for methylating myelin, the sheath around nerve fibres. When that methylation fails, myelin in the spinal cord and peripheral nerves begins to break down. The pattern is not random: it preferentially hits the posterior columns of the spinal cord, which carry vibration and body-position sense, and the lateral corticospinal tracts, which carry motor signals.

The clinical name for that pattern is subacute combined degeneration of the spinal cord — "combined" because both tracts are involved. It is the same injury historically seen in severe pernicious anaemia, and it is the reason a person can walk into a clinic with normal blood counts and still be losing the ability to feel the floor.

Subacute Combined Degeneration: A Spinal Cord Injury That Looks Like Clumsiness

Families almost never see this as a spinal cord problem at first. They see someone who has become clumsy, or lazy, or who keeps dropping their phone.

The earliest symptom is usually sensory: numbness, pins and needles, or a "woolly" feeling in the feet and hands. Because position sense is degraded, walking becomes unsteady — worse in the dark or with eyes closed, worse on stairs. Some people describe walking on cotton wool, or not being able to tell whether their foot has landed. Bladder urgency, difficulty starting urination, and erectile dysfunction are recognised features and are frequently not mentioned to anyone.

The numbers from a 2026 cohort of 81 patients hospitalised across six Sydney teaching hospitals, published in the British Journal of Clinical Pharmacology, put the picture in proportion. Among 100 presentations, the median age was 26. The most common symptoms were gait disturbance (48%), paraesthesia (45%) and weakness (37%). Diagnoses were peripheral neuropathy in 53%, psychosis in 31%, and subacute combined degeneration in 28%.

In adolescents the imaging findings are just as concrete. A 2026 multicentre series and systematic review in European Journal of Pediatrics pooled 59 patients aged 14 to 18: MRI showed long posterior column changes in 89%, and nerve conduction studies showed an axonal sensorimotor neuropathy in 88%. Most of these teenagers presented with sensory complaints only.

The injury is visible on an MRI, and it happens in teenagers who feel fine between sessions.

What families notice first

• Numbness or tingling in the feet, then the hands, often described as "asleep" or "buzzy."
• Unsteadiness in the dark, on stairs, or when standing with eyes closed; grabbing walls and furniture.
• Dropping objects, changes in handwriting, difficulty with buttons or keys.
• New fatigue and reduced stamina in the legs; tripping over nothing.
• Memory and concentration complaints, falling grades, uncharacteristic irritability.
• In some cases, paranoia, hallucinations, or a first episode of psychosis.
• Physical evidence: small metal chargers (the 8-gram cartridges for cream dispensers), tall 640-gram cylinders, balloons, a cream whipper in a bedroom, or repeat deliveries of "gas" canisters.

When it becomes an emergency

• Cannot walk without support, or has fallen repeatedly.
• New loss of bladder or bowel control.
• Confusion, hallucinations, paranoia, or agitation that will not settle.
• Chest pain, sudden breathlessness, or a swollen painful calf — possible clot.
• Blue lips, unresponsiveness, or slowed breathing after use — call 911. NIDA warns that inhalants can cause fatal heart rhythms or suffocation ("sudden sniffing death") even on a first use.

The Blood Test That Comes Back Normal

This is the single most important practical point in this guide, and it is the one most families discover too late.

A doctor who suspects B12 trouble will usually order serum vitamin B12. In nitrous oxide users, that test is close to useless as a screening tool. In the Sydney cohort, serum B12 had a sensitivity of about 22% for detecting the cases with spinal cord involvement — meaning roughly four out of five affected patients would have been missed by it. Holotranscobalamin, the "active" B12 measure, was worse as a screen: sensitivity around 5%, with very high specificity. Worse still, 21% of the patients had elevated serum B12, which is exactly the kind of result that ends an investigation with a reassuring shrug.

The functional markers behave in the opposite way. Homocysteine was 95% sensitive and MMA 93% sensitive for the neurological injury — they rise when B12 is disabled, regardless of how much B12 is floating in the blood. Their weakness is specificity: they are also elevated by kidney disease, other vitamin deficiencies, and common medications, so they confirm that something is wrong with B12 metabolism rather than proving the cause on their own.

Then there is a timing trap. Homocysteine falls quickly once exposure stops — the Sydney authors measured a median half-life of about 14.6 hours, with levels potentially normalising within two to three days even while the neurological damage is ongoing. A person who pauses for a week before the appointment can produce a completely unremarkable panel.

In adolescents, the mismatch is even starker: in the pooled series, 45% had a detectable B12 deficiency, but 92% had elevated homocysteine or MMA. Half the teenagers would have looked "normal" on the vitamin level alone.

The tests to ask for

If there has been nitrous oxide use and any neurological symptom, ask the clinician for:

• Serum vitamin B12 and holotranscobalamin — as a baseline, not as a rule-out.
• Homocysteine and methylmalonic acid — the two that actually move.
• A complete blood count, looking for macrocytosis (enlarged red cells), knowing that anaemia is often absent.
• A neurological examination, and referral to neurology if there is any sensory loss, imbalance, or weakness.
• MRI of the spinal cord if gait or balance is affected — posterior column signal change is the signature.

Tell the clinician about the nitrous oxide directly, and about any B12 supplements or energy drinks already being taken, because both distort the picture.

How Much Is Too Much?

There is no published threshold below which nitrous oxide is known to be safe, and no clinician can give a family a number of balloons that is fine. What the 2026 cohort does provide is the shape of the risk.

The median user in that study inhaled about 17 litres a week, with a median cumulative exposure of 120 litres and a median duration of 91 days. Patients who developed spinal cord involvement had used a median of 364 litres, against 84 litres in those who did not. Each additional 100 litres of cumulative exposure raised the adjusted odds of cord involvement by about 8% and of peripheral neuropathy by about 10%.

The most useful finding is which measure mattered. Weekly volume was not significantly correlated with severity; cumulative volume and duration were. In plain terms: a big night is not the same as a habit, and the total keeps adding up even when each session feels modest. Duration mattered on its own too — every additional day of use slightly raised the odds of cord involvement.

Two further cautions. First, the adolescent review suggests that subclinical B12 deficiency may predispose a young person to injury — meaning a teenager on a restrictive diet, or with untreated coeliac disease, or on long-term acid-suppressing medication, may be injured at lower exposure. Second, most people who try nitrous oxide once do not develop myeloneuropathy. The risk concentrates in heavy, frequent, months-long use, which is exactly the pattern that is easiest to hide.

Beyond the Nerves: Clots, Hallucinations, and the Rest of the Body

Nerve damage is the best-known harm, but it is not the only one.

Blood clots. A systematic review in the Journal of Thrombosis and Thrombolysis collected 14 published cases of thromboembolism in recreational users: deep vein thrombosis, pulmonary embolism, mesenteric, portal and splenic vein thrombosis, cerebral venous sinus thrombosis, stroke, heart attack, and peripheral arterial clots. These were largely young people with no ordinary cardiovascular risk factors. Four percent of the Sydney cohort had a thromboembolic event. The proposed mechanism is the same one that damages nerves — raised homocysteine — and the recommendation in every case was the same: stop the exposure.

Psychosis. Nearly a third of the Sydney cohort (31%) had substance-induced psychosis, with paranoia in 23% and auditory hallucinations in 17%. The reassuring finding is that 97% of those with psychiatric manifestations recovered fully — unlike primary psychotic illness. The less reassuring finding is that a first episode of psychosis is terrifying for a family and is often the event that finally brings someone to care.

The rest. The 2026 pharmacy review lists macrocytic anaemia, bladder and erectile dysfunction, and — less commonly — paralysis. Two adolescents in the Israeli series had raised intracranial pressure. Acute harms include frostbite from expanding gas, falls and head injuries during the high, and asphyxia when the gas is inhaled in an enclosed space, from a bag, or through a mask.

What Treatment Looks Like

Treatment has two halves, and the first one is not medical.

Stop the exposure. Every published series says the same thing: without cessation, nothing improves, and recurrent exposure during recovery can undo it. Homocysteine may normalise within days of stopping, but nerve repair runs on a scale of weeks to months.

Replace the vitamin properly. Guidance summarised in the 2026 review calls for replenishment with intramuscular cyanocobalamin, typically by injection at first rather than an oral supplement, because the problem is not absorption but inactivation. Direct methionine supplementation is being studied and is not universally recommended; routine folic acid is controversial and should be left to the treating physician rather than self-prescribed. High-dose B-vitamin blends bought online are not a substitute for a clinical plan.

Rehabilitate. Physiotherapy for gait and balance, occupational therapy for fine motor tasks, and treatment of neuropathic pain where present.

The outcomes are honest but not hopeless. In the adult cohort, 53% recovered fully, 38% partially, and 10% not at all; among patients with neurological involvement specifically, 44% were left with residual deficits. In adolescents the figures were 27% full recovery and 61% improvement with B12 treatment — a strong argument for speed, since the teenagers who were treated early did better.

And then the part families often skip: why the person was using it. Heavy nitrous oxide use clusters in young adults dealing with anxiety, depression, social isolation, or a life that has narrowed. The psychiatric and substance use pieces need to be treated alongside the spinal cord. A good treatment program will screen for both.

What to Do If It's Your Child or Partner

Look for the physical evidence first, calmly. The 8-gram chargers used in cream dispensers, the tall cylinders sold as "gas," balloons in a glovebox or bedroom bin, a cream whipper that nobody uses for cream, punctured cartridges in the car. Order history on a shared account is often more informative than any conversation.

Start with the body, not the morality. "Have you noticed any numbness or tingling in your feet?" is answerable. "Are you doing whippets?" is not. A young person who will not discuss their weekend will often still describe a symptom that frightens them.

Get the right labs within days, not weeks. Not a general physical in six weeks — a homocysteine and MMA alongside B12, and a neurological exam. If there is imbalance, numbness, or weakness, ask for a neurology referral and an MRI.

Do not wait for a fall. By the time someone cannot walk unassisted, the injury is usually months old; early treatment measurably improves the odds.

Skip the criminal framing. A 2025 Lancet Public Health analysis of the new laws restricting nitrous oxide makes the point directly: measures that target users can make things worse by deterring people from seeking care, while measures targeting suppliers are more likely to reduce harm. Your leverage is a clinician, not a threat. If your child is under 18, decide in advance what you will and will not involve, and say so plainly rather than as a bluff.

Reduce harm while they are still using. If someone will not stop, the honest harm-reduction advice is: never in an enclosed space or a car, never with a bag or mask over the face, never alone, never combined with alcohol or sedatives, and not in the same session as other drugs. Track frequency openly with them, and get B12, homocysteine and MMA checked periodically. This is not endorsement; it is what keeps a person alive and reachable until they are ready.

Expect minimisation. The three sentences you will hear are "it's legal," "everyone does it," and "it wears off in a minute." Legal and safe are different things, everyone does not spend three months in a wheelchair, and the minute is not the part that causes the injury. And look after yourself: support groups and family resources exist for exactly this kind of fear.

Where to Get Help

• SAMHSA National Helpline — 1-800-662-4357. Free, confidential, 24/7, English and Spanish; referrals to sliding-scale and Medicaid-accepting treatment.
• FindTreatment.gov — searchable directory of licensed facilities by location and payment type.
• 988 Suicide and Crisis Lifeline — call or text 988 for suicidal thoughts, severe agitation, or a first psychotic episode.
• America's Poison Centers — 1-800-222-1222 — for acute exposure, frostbite, or a bad reaction right now.
• A neurologist, not a wait-and-see. If there is numbness, imbalance, or weakness, the referral is urgent even if the person feels otherwise fine.

If the person using nitrous oxide is a teenager, the treatment conversation is different from an adult's — adolescent treatment works differently, and talking to a teenager about drugs rarely goes the way a first attempt expects. If they are hearing or seeing things, that is substance-induced psychosis, which is treatable and usually resolves. And if cost is the barrier, there are ways to pay that do not begin with insurance.

The gas is cheap, quiet, and easy to dismiss. The nerve damage it causes is none of those things — and it is one of the few drug injuries where a family's early suspicion, and one correctly chosen blood test, can change what a person's body is able to do for the rest of their life.